AntriaBio

Financials

Investors

Financials

v3.8.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2018
Jun. 30, 2017
Current assets    
Cash $ 78,119 $ 4,486,538
Other current assets 367,810 442,015
Total current assets 445,929 4,928,553
Non-current assets    
Fixed assets, net 4,531,043 5,325,401
Intangible assets, net 38,853 44,322
Deferred lease asset 68,667 86,293
Deposits 56,841 244,341
Total non-current assets 4,695,404 5,700,357
Total Assets 5,141,333 10,628,910
Current liabilities:    
Accounts payable and accrued expenses 3,208,980 1,652,677
Convertible notes payable, net 924,697 10,000
Embedded derivative liability 92,603 0
Deferred lease liability, current portion 121,705 105,295
Interest payable 23,014 2,762
Warrant derivative liability 0 588
Total current liabilities 4,370,999 1,771,322
Non-current liabilities:    
Deferred lease liability, less current portion 212,358 304,575
Deposit liability 25,046 25,046
Total non-current liabilities 237,404 329,621
Total Liabilities 4,608,403 2,100,943
Commitments and Contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 54,073,309 and 49,228,640 shares issued and outstanding, March 31, 2018 and June 30, 2017 54,075 49,230
Additional paid-in capital 82,171,854 72,800,699
Accumulated deficit (81,692,999) (64,321,962)
Total stockholders' equity 532,930 8,527,967
Total Liabilities and Stockholders' Equity $ 5,141,333 $ 10,628,910
v3.8.0.1
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Research and development        
Compensation and benefits $ 1,569,840 $ 1,859,699 $ 4,553,650 $ 5,073,057
Consultants and outside costs 157,759 163,738 521,918 629,996
Material manufacturing costs 219,192 994,366 872,883 2,073,503
Clinical trial costs 65,090 0 1,626,844 0
License costs 0 0 1,178,505 0
Facilities and other costs 484,316 421,292 1,466,123 1,223,847
Research and development 2,496,197 3,439,095 10,219,923 9,000,403
General and administrative        
Compensation and benefits 1,797,385 1,187,379 5,265,306 3,339,332
Professional fees 181,258 278,031 618,251 564,047
Investor relations 64,347 103,657 257,923 259,192
General and administrative 414,295 382,535 1,060,168 940,650
General and administrative 2,457,285 1,951,602 7,201,648 5,103,221
Total operating expenses 4,953,482 5,390,697 17,421,571 14,103,624
Loss from operations (4,953,482) (5,390,697) (17,421,571) (14,103,624)
Other income (expense)        
Interest income 116 0 977 0
Rent income 31,406 5,306 95,082 5,306
Interest expense (53,363) 0 (53,510) (1,595)
Derivative gains 7,487 792 7,985 11,517
Total other income (expense) (14,354) 6,098 50,534 15,228
Net loss (4,967,836) (5,384,599) (17,371,037) (14,088,396)
Warrant modification deemed dividend 0 (3,366,070) 0 (3,366,070)
Net loss attributable to common stock $ (4,967,836) $ (8,750,669) $ (17,371,037) $ (17,454,466)
Net loss per common share - basic and diluted $ (0.09) $ (0.21) $ (0.32) $ (0.44)
Weighted average number of common shares outstanding - basic and diluted 54,073,309 42,216,495 53,573,410 39,446,695
v3.8.0.1
Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (17,371,037) $ (14,088,396)
Amortization of intangible asset 5,469 5,469
Amortization of debt discount 31,697 0
Depreciation expense 800,174 829,258
Stock-based compensation expense 4,175,493 3,537,963
Derivative gains (7,985) (11,517)
Warrant expense 543,507 0
Changes in operating assets and liabilities:    
Decrease (increase) in other assets 74,205 (233,676)
Decrease in deferred lease asset 17,626 0
Increase in accounts payable and accrued expenses 1,556,303 381,676
Increase (decrease) in interest payable 20,252 (2,800)
Decrease in deferred lease liability (75,807) (85,802)
Net Cash Used In Operating Activities (10,230,103) (9,667,825)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets (5,816) (300,302)
Return of security deposit 187,500 187,500
Net Cash Provided by (Used In) Investing Activities 181,684 (112,802)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments on lease payable 0 (23,128)
Proceeds on convertible notes payable 1,200,000 0
Proceeds from issuance of equity financing 4,500,000 10,861,499
Payment of placement agent compensation and issuance costs (60,000) (683,194)
Net Cash Provided by Financing Activities 5,640,000 10,155,177
Net (decrease) increase in cash (4,408,419) 374,550
Cash - Beginning of Period 4,486,538 4,062,013
Cash - End of Period 78,119 4,436,563
Cash Paid During the Period for:    
Taxes 0 0
Interest 0 0
Non-Cash Transactions:    
Fixed assets acquired through accounts payable and accrued expenses 0 5,400
Warrant value recorded as issuance costs 0 516,550
Warrant value recorded as debt discount 217,000 0
Embedded derivative value recorded as debt discount 100,000 0
Conversion of note payable into common stock 0 50,000
Conversion of interest payable into common stock 0 9,517
Fair value of warrant modifications recorded as a deemed dividend $ 0 $ 3,366,070